E!8280, NUPLEX, EPIGENICA AB
| Reference number | |
| Coordinator | Epigenica AB |
| Funding from Vinnova | SEK 5 000 000 |
| Project duration | October 2025 - April 2028 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
The project will develop a first-in-class blood-based test analysing multiple epigenetic markers for early cancer detection. The aim is to move the technology from prototype to a research-use-only product and later regulatory studies. Using AI-driven data analysis and proprietary multiplexing, we will improve sensitivity and specificity for multi-cancer diagnostics
Expected effects and result
The project will deliver a commercially ready RUO product and a validated software platform suitable for clinical studies. This is expected to reduce mortality through earlier cancer detection, lower healthcare costs, and decrease cancer-related deaths by an estimated 6–7 percent. The technology can be run in standard labs, reducing disparities and making multi-cancer testing widely accessible.
Planned approach and implementation
The work is divided into three phases: validation of biomarkers and scale-up to high-throughput, a large retrospective study of biobank samples, and development of an integrated AI software and related platform. Clinical pilot testing will be performed and we will design a real world evidence methodology and decision-support tool, enabling a full product solution.